Stock 4174 OBI PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company OBI Pharma, Inc.

Equities

4174

TW0004174008

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 03:30:00 13/05/2024 am IST 		5-day change 1st Jan Change
61.2 TWD -0.81% Intraday chart for OBI Pharma, Inc. -0.16% -11.82%
10/05 Obi Pharma, Inc. Announces the Termination of License Agreement with Odeon for the Rights of Obi-999 and Obi-833 in China, Hong Kong and Macau CI
26/03 OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

OBI Pharma, Inc. is a Taiwan-based company principally engaged in the development of new pharmaceuticals. The Company mainly operates its businesses through the research and development of novel cancer and infectious disease therapies. It also develops next generation active immunotherapies to treat cancers, including lung, prostate, pancreatic, stomach and ovarian cancers. It is engaged in the development of OBI-822 (formerly OPT-822/821), an active immunotherapy new drug for metastatic breast cancer; the research and development of therapeutic vaccine OBI-833 for the treatment of new generation of cancers, as well as the development of cancer testing reagent OBI-868.

Sales per Business

TWD in Million2022Weight2023Weight Delta
CDMO
95.1 %
3 57.5 % 40 95.1 % +1,358.80%
New Anticancer Drug
4.9 %
2 42.5 % 2 4.9 % +1.40%

Sales per region

TWD in Million2022Weight2023Weight Delta
Taiwan
96.2 %
3 72.9 % 40 96.2 % +1,065.18%
Others
3.8 %
1 27.1 % 2 3.8 % +21.97%

Managers

Managers TitleAgeSince
Heidi Wang CEO
 Chief Executive Officer - 02/23/02
Chih Chuan Chen DFI
 Director of Finance/CFO - -
Kuo Lin Kao AUD
 Comptroller/Controller/Auditor - 20/17/20

Members of the board

Members of the board TitleAgeSince
Ta Meng Tseng BRD
 Director/Board Member 66 07/13/07
Chih Chuan Chen DFI
 Director of Finance/CFO - -
Tai Chang Wang BRD
 Director/Board Member 65 -
Lung Yeh Cho BRD
 Director/Board Member - 07/13/07
Chen Yue Feng BRD
 Director/Board Member - -
Chung Ming Chang BRD
 Director/Board Member - -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 229,439,374 151,779,374 ( 66.15 %) 191,000 ( 0.0832 %) 66.15 %

Shareholders

NameEquities%Valuation
Storebrand Asset Management AS
0.009425 %
21,624 0.009425 % 40 841 NT$
P+, Pensionskassen for Akademikere (Investment Management)
0.003453 %
7,923 0.003453 % 14 964 NT$
Amundi Asset Management SA (Investment Management)
0.002665 %
6,115 0.002665 % 11 549 NT$

Company contact information

OBI Pharma, Inc.

19th Floor No. 3 Yuan Qu Street

115 03, Taipei

+

http://www.obipharma.com
address OBI Pharma, Inc.(4174)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Sales per region

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
OBI PHARMA, INC. Stock OBI Pharma, Inc.
-11.82% 44Cr
MODERNA, INC. Stock Moderna, Inc.
+26.37% 4.5TCr
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.01% 4.26TCr
LONZA GROUP AG Stock Lonza Group AG
+46.00% 4.18TCr
CELLTRION, INC. Stock Celltrion, Inc.
-5.31% 2.9TCr
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.34% 2.61TCr
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.69% 1.9TCr
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+6.23% 1.28TCr
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.99% 1.21TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.38% 1.18TCr
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 4174 Stock
  4. Company OBI Pharma, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW